Advertisement

Topics

Novartis’ Cosentyx beats J&J’s Stelara in psoriasis trial

06:34 EST 16 Jan 2018 | PharmaTimes

Novartis has released trial data showing that Cosentyx was “significantly more effective” than Johnson & Johnson’s rival biologic Stelara in achieving clear skin in patients with psoriasis.

Original Article: Novartis’ Cosentyx beats J&J’s Stelara in psoriasis trial

NEXT ARTICLE

More From BioPortfolio on "Novartis’ Cosentyx beats J&J’s Stelara in psoriasis trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...